CRIS - キュ―リス (Curis Inc.) キュ―リス

 CRISのチャート


 CRISの企業情報

symbol CRIS
会社名 Curis Inc (キュ―リス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 キュリス(Curis Inc.)は癌治療薬の開発、商業化を求めるバイオテクノロジー企業である。同社の薬品候補は経口可能なヒストン脱アセチル化酵素(HDAC)の小分子阻害剤CUDC-907、ホスファチジルイノシトール-3-キナーゼ(PI3K)酵素を含む。CUDC-907はクラスI、IIのHDAC、及びクラスIのPI3K酵素の経口二重阻害剤である。CA-170は免疫活性化の負の調節因子として独立して機能するプログラムされた死亡リガンド-1(PDL1)およびT細胞活性化のVドメインIgサプレッサー(VISTA)免疫チェックポイントタンパク質を選択的に標的化するために設計される経口小分子薬物候補である。CA-4948はトール様受容体またはある種のインターロイキン受容体シグナル伝達経路のトランスデューサであるインターロイキン-1受容体関連キナーゼ4(IRAK4)キナーゼを阻害するために設計される経口小分子薬物候補である。   キュ―リスは、癌治療の研究開発に従事する米国企業。社内および共同で研究開発プログラムを行っている。癌薬剤候補は、リンパ腫および多発性骨髄腫治療の「CUDC-907」、固形腫瘍およびリンパ腫治療の「CUDC-427」、高度な基底細胞癌の治療のために承認された薬「Erivedge」がある。   Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination the with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.
本社所在地 4 Maguire Road Lexington MA 02421 USA
代表者氏名 James R. McNab ジェームズ・R・マクナブ
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-503-6500
設立年月日 36557
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 55人
url www.curis.com
nasdaq_url https://www.nasdaq.com/symbol/cris
adr_tso
EBITDA EBITDA(百万ドル) -39.14600
終値(lastsale) 1.92
時価総額(marketcap) 63707800.32
時価総額 時価総額(百万ドル) 65.03505
売上高 売上高(百万ドル) 10.53200
企業価値(EV) 企業価値(EV)(百万ドル) 63.11205
当期純利益 当期純利益(百万ドル) -42.89600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Curis Inc. revenues increased 15% to $4.8M. Net loss decreased 35% to $19.4M. Revenues reflect Royalties increase of 13% to $4.9M Research and development net increase of 58% to -$42K. Lower net loss reflects Research_development Expenses B/F decrease of 42% to $13.9M (expense) Stock-Based Compensation Expense in SGA decrease of 21% to $1.6M (expense).

 CRISのテクニカル分析


 CRISのニュース

   Curis (CRIS) Q1 2022 Earnings Call Transcript  2022/05/06 05:01:00 The Motley Fool
CRIS earnings call for the period ending March 31, 2022.
   Curis Inc.''s (CRIS) CEO Jim Dentzer on Q1 2022 Results - Earnings Call Transcript  2022/05/05 22:55:21 Seeking Alpha
Curis, Inc. (NASDAQ:NASDAQ:CRIS) Q1 2022 Earnings Conference Call May 5, 2022 4:30 P.M.
   Curis GAAP EPS of -$0.18 misses by $0.02, revenue of $2.06M misses by $0.49M  2022/05/05 20:10:40 Seeking Alpha
Curis press release (NASDAQ:CRIS): Q1 GAAP EPS of -$0.18 misses by $0.02.Revenue of $2.06M (-5.9% Y/Y) misses by $0.49M.Shares -2.2%.
   Curis Reports First Quarter 2022 Financial Results and Business Update  2022/05/05 20:01:00 investors Curis
   Curis to Release First Quarter 2022 Financial Results and Hold Conference Call on May 5, 2022  2022/04/28 20:00:00 investors Curis
   Marin Software, QuinStreet lead postmarket gainers; Annexon, Dogness among losers  2022/01/06 22:29:07 Seeking Alpha
Gainers: Marin Software MRIN +43%, QuinStreet (QNST) +5%, Axsome Therapeutics (AXSM) +4%, CarParts.com PRTS +3%, Curis CRIS +3%.Losers: Annexon (ANNX) -5%, Dogness (DOGZ) -4%,
   Curis provides update on phase 1/2 blood cancer study of CA-4948  2022/01/06 14:25:53 Seeking Alpha
   How Could You Make A Quick Recovery From Curis Inc. (NASDAQ: CRIS) Given A -463.67% Drop From Highs?  2021/12/18 20:00:00 Marketing Sentinel
During the last session, Curis Inc. (NASDAQ:CRIS)s traded shares were 3.56 million, with the beta value of the company hitting 2.84. At the end of the trading day, the stocks price was $4.79, reflecting an intraday gain of 7.16% or $0.32. The 52-week high for the CRIS share is $17.40, that puts it down -263.26 How Could You Make A Quick Recovery From Curis Inc. (NASDAQ: CRIS) Given A -463.67% Drop From Highs? Read More »
   Curis to be Added to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF  2021/12/15 13:00:00 investors Curis
   Curis (NASDAQ:CRIS) Stock Rating Lowered by Zacks Investment Research  2021/12/14 01:34:42 Dakota Financial News
Curis (NASDAQ:CRIS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Monday, Zacks.com reports. According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. […]
   Curis (NASDAQ:CRIS) Rating Increased to Buy at Zacks Investment Research  2021/12/08 06:20:44 ETF Daily News
Curis (NASDAQ:CRIS) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued to investors on Monday, Zacks.com reports. The firm presently has a $5.00 price objective on the biotechnology companys stock. Zacks Investment Researchs target price would indicate a potential upside of 2.25% from the companys [] The post Curis (NASDAQ:CRIS) Rating Increased to Buy at Zacks Investment Research appeared first on ETF Daily News .
   Colony Family Offices LLC Cuts Stock Holdings in Curis, Inc. (NASDAQ:CRIS)  2021/12/06 15:48:42 Transcript Daily
Colony Family Offices LLC trimmed its position in shares of Curis, Inc. (NASDAQ:CRIS) by 28.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,387 shares of the biotechnology companys stock after selling 8,000 shares during the quarter. Curis accounts for approximately 0.1% of []
   Curis (NASDAQ:CRIS) Downgraded to Hold at Zacks Investment Research  2021/12/01 01:08:41 Transcript Daily
Curis (NASDAQ:CRIS) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and []
   Why Do Investors Buy Stock In Curis Inc. (CRIS)?  2021/11/29 12:30:00 Marketing Sentinel
Curis Inc. (NASDAQ:CRIS) has a beta value of 2.78 and has seen 1.59 million shares traded in the last trading session. The company, currently valued at $478.07M, closed the last trade at $5.10 per share which meant it gained $0.02 on the day or 0.39% during that session. The CRIS stock price is -241.18% off Why Do Investors Buy Stock In Curis Inc. (CRIS)? Read More »
   Amalgamated Bank Purchases New Position in Curis, Inc. (NASDAQ:CRIS)  2021/11/24 10:40:41 Transcript Daily
Amalgamated Bank purchased a new stake in Curis, Inc. (NASDAQ:CRIS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 15,818 shares of the biotechnology companys stock, valued at approximately $128,000. Several other hedge funds and other institutional investors have also recently made changes []

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 キュ―リス CRIS Curis Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)